mRNA lipid nanoparticle vaccines: current status, challenges and future prospects
Zhineng Wu, Jinghu Lou, Yi Cheng, Meng Li, Zengming Wang, Nan Liu, Xiang Gao, Aiping Zheng, Hui Zhang · 2026
Read mRNA lipid nanoparticle vaccines: current status, challenges and future prospects by Zhineng Wu, Jinghu Lou, Yi Cheng, Meng Li, Zengming Wang, Nan Liu, Xiang Gao, Aiping Zheng, Hui Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13620059.txt.
Description
Zhineng Wu and eight colleagues review where mRNA vaccines carried in lipid nanoparticles stand now and what holds them back. The COVID-19 vaccines proved the platform can be designed fast, made at scale, and drive the body to produce a target protein in place. Tiny fat bubbles protect the fragile mRNA on its way into cells, which the authors call the key enabling step.
Chapters move through mRNA engineering, particle makeup and delivery, immune responses, and clinical progress to date. Standing problems include keeping formulas stable in storage, limiting side reactions, and making protection last longer. Newer ideas covered here include heat-stable recipes, particles aimed at specific tissues, fresh RNA formats, and computer-aided design of both RNA sequences and lipid materials. The authors frame these strands as one design problem rather than separate fixes.
Catalog record
| CREATOR | Zhineng Wu, Jinghu Lou, Yi Cheng, Meng Li, Zengming Wang, Nan Liu, Xiang Gao, Aiping Zheng, Hui Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 107 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |